Clazakizumab: Difference between revisions
Content deleted Content added
m Undid revision 824509160 by Tyranitar Man (talk) -- overlink |
Sun Creator (talk | contribs) →top: General fixes, replaced: a aglycosylated → an aglycosylated |
||
| Line 37: | Line 37: | ||
}} |
}} |
||
'''Clazakizumab''' (formerly '''ALD518''' and '''BMS-945429'''), an [[investigational drug]], is |
'''Clazakizumab''' (formerly '''ALD518''' and '''BMS-945429'''), an [[investigational drug]], is an [[aglycosylated]], humanized rabbit [[monoclonal antibody]] against [[interleukin-6]].<ref name="Handbook">{{cite book|editor1-link=Stefan Dübel, Janice M. Reichert (eds)|title=Handbook of Therapeutic Antibodies, Volume 2|date=2007|publisher=Wiley Blackwell|page=987|url=https://books.google.com/books?id=svHsBQAAQBAJ&pg=PA987&lpg=PA987&dq=Clazakizumab,+BMS-945429+ALD518&source=bl&ots=OSkfdXWflh&sig=SDM6MUhRVekTcRVaQ6SgemQgXAw&hl=en&sa=X&ved=0ahUKEwjW6a-ipdnRAhUpxlQKHUHrCMwQ6AEIPTAG#v=onepage&q=Clazakizumab%2C%20BMS-945429%20ALD518&f=false|accessdate=January 23, 2017}}</ref> Clazakizumab was developed by [[Bristol Myers Squib]] and [[Alder Biopharmaceuticals]]. A preliminary randomized, double-blind, placebo-controlled, [[phase 2 clinical trial|phase 2]] dose-ranging study of clazakizumab in [[psoriatic arthritis]] patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a [[dose-response effect]].<ref name="ArthRheum1">{{cite journal|vauthors=Mease PJ, Gottlieb AB|display-authors=etal|title=The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis.|journal=Arthritis Rheumatol|date=September 2016|volume=68|issue=9|pages=2163–73|doi=10.1002/art.39700}}</ref> |
||
==See also== |
==See also== |
||
Revision as of 22:04, 6 December 2019
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| Other names | ALD518, BMS-945429 |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C6426H9972N1724O2032S42 |
| Molar mass | 145.2 kg/mol g·mol−1 |
Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6.[1] Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.[2]
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
References
- ^ Handbook of Therapeutic Antibodies, Volume 2. Wiley Blackwell. 2007. p. 987. Retrieved January 23, 2017.
- ^ Mease PJ, Gottlieb AB, et al. (September 2016). "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis". Arthritis Rheumatol. 68 (9): 2163–73. doi:10.1002/art.39700.